In a world where cancer continues to be a persistent threat, the NTRK fusion gene positive advanced solid tumors market offers a glimmer of hope. With a projected CAGR of 5.9% and a projected value of US$ 230 Million in 2033, it's no surprise that this market is capturing the attention of healthcare professionals and investors alike.
| Data Points | Key Statistics |
|---|---|
| Expected Market Value in 2023 | US$ 130 million |
| Projected Market Value in 2033 | US$ 230 million |
| Growth Rate (2023 to 2033) | 5.9% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Advancements in precision medicine are one of the prominent drivers of the NTRK Fusion Gene Positive Advanced Solid Tumors market. Precision medicine is a new approach to healthcare that is based on a person's unique genetic makeup, lifestyle, and medical history. It is designed to help healthcare providers deliver more effective and personalized treatments for cancer patients. With the rise of precision medicine, healthcare providers are now better equipped to diagnose and treat NTRK Fusion Gene Positive Advanced Solid Tumors more effectively. This is helping to drive the growth of the market by increasing demand for targeted therapies and personalized treatment plans.
A prominent driver of the NTRK fusion gene positive advanced solid tumors market is the growing understanding of the genetic roots of cancer. Scientists and healthcare professionals have made significant strides in understanding the genetic mutations that contribute to the development of NTRK Fusion Gene Positive Advanced Solid Tumors. This has led to the development of new and innovative treatments that target the specific genetic mutations that cause these cancers. As a result, patients with NTRK fusion gene positive advanced solid tumors are now able to receive more effective and targeted treatments that are tailored to their unique needs.
The rise of personalized treatment plans is also contributing to the growth of the market for NTRK fusion gene positive advanced solid tumors by increasing demand for genetic testing. Genetic testing is used to identify the specific genetic mutations that contribute to the development of NTRK fusion gene positive advanced solid tumors.
For instance, in January 2023, Merck announced that its anti-PD-1 therapy KEYTRUDA has been granted approval by the US Food and Drug Administration (FDA) as a standalone treatment for adult patients with stage IB, II, or IIIA non-small cell lung cancer (NSCLC). The approval allows for the use of KEYTRUDA after surgical resection and platinum-based chemotherapy. The treatment is meant to be given to patients with T2a ≥ 4 centimetres in size.
The rise of personalized treatment plans is also driving the growth of the market by increasing demand for genetic counsellors and other healthcare professionals who specialize in precision medicine.
The North American market for NTRK fusion gene positive advanced solid tumors has seen significant growth in recent years. Leading pharmaceutical companies have made substantial investments in research and development, resulting in the approval of several drugs that target NTRK fusion gene positive advanced solid tumors.
As a result, North America is poised to continue its leadership role in the development of the NTRK fusion gene positive advanced solid tumors market in the coming years.
Principal Consultant
The most lucrative end user for the NTRK fusion gene positive advanced solid tumors market is the healthcare sector, specifically hospitals. With a high prevalence of advanced solid tumours and a growing focus on precision medicine, hospitals are at the forefront of the use of NTRK fusion gene positive advanced solid tumors treatments.
A patient with tumors who has mutated genes NTRK is called NTRK fusion gene positive tumors. Although NTRK fusions are rare and account to nearly 1% of solid tumors, the exact frequency is quite unclear. DNA Next Generation Sequencing (NSG) technology is a precise method to detect NTRK fusion genes. It has high specificity and sensitivity.
It can detects gene partners that may have high clinical implications in treatment. Currently Commercialized techniques such as DNA NGS panels, Foundation One may not detect NTRK fusions.
NTRK fusions has higher prevalence rate as they are found in most of solid cancer types. This is expected to drives NTRK fusion gene positive advanced solid tumors market. NTRK is a unique gene which has implications in many types of cancers and the development of latest drugs is expected to drive NTRK fusion gene positive advanced solid tumors market.
However, Poor healthcare infrastructure and high costs associated with genetic screening of NTRK fusion genes may hamper growth of NTRK fusion gene positive advanced solid tumors market in the future.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The global NTRK fusion gene positive advanced solid tumors market is estimated to show rapid growth over forecast period owing to technical advancements. Early screening and detection of NTRK mutation genes in people will contribute to NTRK fusion gene positive advanced solid tumors market.
Global NTRK fusion gene positive advanced solid tumors market has high potential due to development of novel therapeutics in near future for treating different types of cancers. Recently in 2019, FDA approved NTRK inhibitors like Entrectinib manufactured by Genentech Inc., for effective treatment of NTRK fusion gene positive advanced solid tumors.
The global NTRK fusion gene positive advanced solid tumors market is expected to be dominated by North America owing to rising cancer clinical research and development activities. Latin America market is emerging in NTRK fusion gene positive advanced solid tumors market due to increased spending on healthcare infrastructure.
Europe market is expected to be the second most growing region in the global NTRK fusion gene positive advanced solid tumors market owing to early diagnosis and treatment adoption. NTRK fusion gene positive advanced solid tumors market in East Asia and South Asia is expected to show significant growth due to improving healthcare infrastructure.
Middle East and Africa market is expected to be least lucrative region in the NTRK fusion gene positive advanced solid tumors market due to poor healthcare facilities and less disease screening facilities.
Examples of some of the market participants in NTRK fusion gene positive advanced solid tumors market identified across the value chain includes Bayer A.G., Merck & Co., Inc., F. Hoffmann-La Roche AG, Glaxosmithkline plc, Pfizer Inc., Plexxikon, Daiichi Sankyo Company Limited, Deciphera Pharmaceuticals, Inc., Eli Lilly and company, Exelixis, Inc., Cephalon, Inc., and others.
The research report on NTRK fusion gene positive advanced solid tumors market presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and, statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies.
The research report on NTRK fusion gene positive advanced solid tumors market provides analysis and information according to market segments such as geographies, application, and end user.
The report on NTRK fusion gene positive advanced solid tumors market is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.
The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
The global NTRK fusion gene positive advanced solid tumors market is classified on the basis of Indication and End User.
Explore Healthcare Insights
View Reports
NTRK Fusion Gene Positive Advanced Solid Tumors Market
